Astellas Pharma Global DevelopmentInc.
Gilteritinib(Astellas Pharma Global Development, Inc.)은 Acute Myeloid Leukemia 표적 ADC로, Acute Myeloid Leukemia (AML); Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation 영역에서 개발·상용화 중입니다. 작용기전: target the IRAK1/4-cholesterol pathway in glioblastoma, brigatinib to target the MARK2/3-Hippo pathway. Phase 2에서 효능·안전성 신호를 검증 중입니다. OS: 9.3. PK: t½ 113 days. 차별점: novel molecules in combination regimens, which are enhancing remission rates.
Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML); Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
Recruiting
gene therapy as a significant future direction, detailing advancements i
linker demonstrated improved some pharmacokinetic properties such as half-life (T 1/2
novel molecules in combination regimens, which are enhancing remission rates
target the IRAK1/4-cholesterol pathway in glioblastoma, brigatinib to target the MARK2/3-Hippo pathway
apoptosis and reduced ALK protein levels
EGFR and absent VEGFR inhibition, are in theory associated with low
resistance to second‑generation tyrosine kinase inhibitors in anaplastic lymphoma kinase (ALK)‑rearranged non‑sm
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Astellas Pharma Global DevelopmentInc.
Gilteritinib(Astellas Pharma Global Development, Inc.)은 Acute Myeloid Leukemia 표적 ADC로, Acute Myeloid Leukemia (AML); Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation 영역에서 개발·상용화 중입니다. 작용기전: target the IRAK1/4-cholesterol pathway in glioblastoma, brigatinib to target the MARK2/3-Hippo pathway. Phase 2에서 효능·안전성 신호를 검증 중입니다. OS: 9.3. PK: t½ 113 days. 차별점: novel molecules in combination regimens, which are enhancing remission rates.
Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML); Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
Recruiting
gene therapy as a significant future direction, detailing advancements i
linker demonstrated improved some pharmacokinetic properties such as half-life (T 1/2
novel molecules in combination regimens, which are enhancing remission rates
target the IRAK1/4-cholesterol pathway in glioblastoma, brigatinib to target the MARK2/3-Hippo pathway
apoptosis and reduced ALK protein levels
EGFR and absent VEGFR inhibition, are in theory associated with low
resistance to second‑generation tyrosine kinase inhibitors in anaplastic lymphoma kinase (ALK)‑rearranged non‑sm
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.